Complete Coverage A phase 3 trial showed a trend toward improved PFS with ixazomib plus lenalidomide and dexamethasone.
Clinicians are not following guideline recommendations, as prognostic biomarker testing for CLL/SLL remains low and affects treatment selection.
Clinicians are not following guideline recommendations, as prognostic biomarker testing for CLL/SLL remains low and affects treatment selection.
A phase 1 trial demonstrated antitumor activity of liso-cel plus ibrutinib with low rates of grade 3 or higher CRS and neurotoxicity among heavily pretreated patients with CLL/SLL.
The phase 3 UNITY-CLL study showed prolonged PFS with the PI3K inhibitor plus anti-CD20 therapy combination.
LOXO-305 treatment of heavily pretreated CLL/SLL resulted in durable, high response rates in a phase 1/2 trial.
The average spending per hospitalization during the course of 5 years was higher for survivors of NHL compared with controls ($16,950 vs. $13,474).
Axi-cel demonstrated significant clinical benefit as a first-line treatment for patients with high-risk large B-cell lymphoma.
The bispecific CAR-T therapy targets CD20 and CD19.
Response rates have improved as phase 1 studies shifted from chemotherapy to targeted agents for hematologic malignancies.
Ibrutinib was associated with a longer duration until second-line treatment, regardless of risk status, compared with CIT among patients with CLL.
Hospitalization due to MM has increased over the last 10 years, but in-hospital mortality has declined.
A fully human BCMA-directed CAR-T product showed clinical activity in patients with relapsed/refractory multiple myeloma.
Even patients who did not achieve MRD negativity at 1 year had stable or decreasing disease levels.
A CAR-T therapy for myeloma that is manufactured using a unique process showed clinical activity and appeared safe, even in the outpatient setting.
The combination was also associated with improvements in progression-free and overall survival.
Confirmed undetectable MRD after 12 cycles may result in treatment discontinuation.
Asciminib may be a new treatment option for patients with chronic myeloid leukemia in the chronic phase (CML-CP).
There may be no relapse-free survival or overall survival benefits with posttransplant azaciditine in patients with high-risk AML or MDS.
Study results suggested that the discontinuation of tyrosine kinase inhibitors for chronic myeloid leukemia may be safe, without limiting remission.
Load More